Please login to the form below

Not currently logged in
Email:
Password:

Exelixis

This page shows the latest Exelixis news and features for those working in and with pharma, biotech and healthcare.

BMS eyes approval for second Opdivo combo in kidney cancer

BMS eyes approval for second Opdivo combo in kidney cancer

Detailed results presented at ESMO 2020 virtual congress. Bristol Myers Squibb has reported positive data for a combination of its PD-L1 inhibitor Opdivo with Exelixis’ Cabometyx in renal cell carcinoma ... BMS and Exelixis have already completed their

Latest news

More from news
Approximately 5 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Charting a course for expansion Charting a course for expansion

    Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug Cabometyx (cabozantinib) from Californian biotech Exelixis.

  • Deal Watch March 2016 Deal Watch March 2016

    Two deals involved products at a later stage of development: Dr Reddy's licence for Xenoport's phase II product XP23829 for plaque psoriasis, and Ipsen's licence for Exelixis's ... Collaboration – discovery, development &commercialisation. $965.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Exelixis appoints Andrew Peters to newly created position Exelixis appoints Andrew Peters to newly created position

    He joins the biotech as its vice president, strategy. California, US-based biotechnology group Exelixis has appointed Andrew Peters as vice president of strategy. ... His familiarity with Exelixis and the biotech landscape should make for a seamless

  • Decibel Therapeutics expands leadership team Decibel Therapeutics expands leadership team

    Prior to this, he was president and chief executive of Exelixis and served as president of Bayer Biotechnology, overseeing the business development, manufacturing and R&D of the company's biological

  • Frances Heller joins BMS senior management

    Heller comes to BMS from Exelixis, a San Francisco-based genomics drug discovery company, where she was executive vice president of business development.

More from appointments
Approximately 1 fully matching, plus 2 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

Switzerland
Switzerland: a life sciences hub
Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications
OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month
Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...

Infographics